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Abstract
Purpose
153Sm-ethylenediaminetetramethylenephosphonic
acid (EDTMP; Quadramet®) is indicated for the treatment of
painful bone metastases, whereas zoledronic acid (Zometa®)
is indicated for the prevention of skeletal complications.
Because of the different therapeutic effects, combining the
treatments may be beneficial. Both, however, accumulate in
areas with increased osteoblastic activity. Possible drug
interactions were investigated.
Methods Patients with hormone-refractory prostate cancer
were treated with 18.5 MBq/kg
153Sm-EDTMP in weeks 1
and 3 and with 37 MBq/kg in week 15. Treatment with 4 mg
zoledronic acid began in week 3 and continued every
4 weeks through week 23. In weeks 3 and 15, zoledronic
acid was administered 2 days before
153Sm-EDTMP
treatment. Urine was collected 48 h after injection of
153Sm-EDTMP, and whole-body images were obtained 6,
24 and 48 h post-injection. The effect of zoledronic acid on
total bone uptake of
153Sm-EDTMP was measured indirectly
by the cumulative activity excreted in the urine in weeks 1, 3
and 15. Biodistribution, safety, tolerability and effect on
prostate-specific antigen level were also studied.
Results The urinary excretion in week 3 divided by the
urinary excretion in week 1 (baseline) times 100% was
mean 98.4±11.6% (median 96.2%). From week 1 to 15,
after four zoledronic acid treatments, the mean ratio was
101.9±10.7% (median 101.8%). Bioequivalence could be
concluded by using a two-sample t test for both per-
protocol (n=13) and full-analysis sets (n=18). Toxicity was
comparable to of monotherapy with
153Sm-EDTMP.
Conclusion Zoledronic acid treatment does not influence
153Sm-EDTMP skeletal uptake. Combined treatment is
feasible and safe.
Keywords Bonemetastases.Pain.Samarium.
Zoledronicacid.Nuclear therapy
Introduction
Prostate cancer is one of the most common malignancies
worldwide. Approximately 50–70% of patients present at a
locally advanced stage, and ~15–30% have bone metastases
at the time of diagnosis [1]. Metastatic disease may be
found upon presentation or may develop after treatment for
localised disease.
In advanced prostate cancer, spread of the disease to the
skeleton occurs in the majority of patients, with skeletal
metastases being predominantly osteoblastic in nature. The
clinical course of metastatic bone disease in prostate cancer
is relatively long, with patients experiencing complications
over a period of several years. These complications include
bone pain, fractures, hypercalcemia and spinal cord com-
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quality of life. Careful attention to pain management by care
providers is crucial.
External radiotherapy is the best treatment for localised
metastatic bone pain [2]. Nevertheless, external beam
radiotherapy is less favourable when the disease has
metastasised globally because the effective radiation dose
is limited by toxicity in adjacent or overlapping critical
structures and organs. Radionuclide therapy has been
proposed as an alternative modality for the management
of bone pain. These radiopharmaceuticals localise prefer-
entially in active bone and mainly at metastatic lesions,
allowing site-directed radiotherapy [3].
Samarium-153-ethylenediaminetetramethylphosphonic
acid (
153Sm-EDTMP or
153Sm-lexidronam; Quadramet®) is
a radiopharmaceutical compound that has an affinity for
skeletal tissue and concentrates in areas of increased bone
turnover [4].
153Sm-EDTMP is indicated for the relief of
pain in patients with osteoblastic metastatic bone lesions at
a dose of 37 MBq/kg (1.0 mCi/kg). With a half-life of
46.3 h, the radioisotope emits a 103-keV gamma ray (29%)
for external imaging and beta particles (average energy
233 keV) for localised radiotherapy. The average range of
emission of
153Sm-electrons is only 1.7 mm in bone,
limiting the exposure of bone marrow and other adjacent
tissues to radiation. The combination of radiopharmaceuti-
cals with other treatment options (systemic or local) needs
to be investigated to further improve efficacy [5, 6].
To minimise the incidence of skeletal-related events,
bisphosphonates may be indicated as a systemic treatment
for patients with osseous metastases. Bisphosphonates are
characterised by a central phosphorus–carbon–phosphorus
structure. They bind tightly to the calcified bone matrix and
are powerful inhibitors of osteoclast-mediated bone resorp-
tion. Zoledronic acid, a new-generation bisphosphonate,
exhibits a more potent inhibitory activity of osteoclasts
compared with other bisphosphonates [7]. In July 2002, the
European Agency for the Evaluation of Medicinal Products
granted marketing authorisation in the European Union for
Zometa
® (zoledronic acid) for the prevention of skeletal-
related events in patients with advanced malignancies
involving bone. These malignancies include multiple
myeloma, prostate cancer, breast cancer, lung cancer, renal
cancer and other solid tumors.
To manage potential complications related to bone
metastasis in prostate cancer (pain, pathological fractures,
etc.), several approaches are being developed, including
radiopharmaceuticals and bisphosphonates. With regard to
pain relief, radiopharmaceuticals are indicated in prostate
cancer. In contrast, the efficacy of bisphosphonates for pain
management has not been clearly demonstrated [8].
Combined treatment with both pharmaceuticals may im-
prove palliative care and enhance overall efficacy [9].
However, there are conflicting data as to whether
bisphosphonates inhibit the uptake of radiolabelled phospho-
nates in bone metastases. Some studies reported that bone
uptakeof
99mTc-labelled bone scanning agents was decreased
in patients receiving etidronate intravenously or orally [10–
12]. On the other hand, other studies reported the feasibility
of the combined use of bisphosphonates with radiolabelled
phosphonates [13–15]. With regard to bone-seeking radio-
pharmaceuticals, proper studies evaluating the influence of
bisphosphonates on bone uptake are non-existent.
Patients with an indication for
153Sm-EDTMP therapy
often receive monthly infusions of bisphosphonates such as
zoledronic acid, and these related compounds are both taken
up by the bone. Thus, the purpose of the present clinical trial
was to investigate the effects of zoledronic acid on the bone
uptake of
153Sm-EDTMP and on bone metabolism and to
assess the safety of the combined use of both products.
Materials and methods
Study population
Patients with histologically documented adenocarcinoma of
theprostate,progressivehormone-refractorydiseaseandmore
than one bone metastasis were included in this open-label
prospective study. Other inclusion criteria were a Karnofsky
performance status of at least 70%, life expectancy of at least
8 months, age ofat least 18 years and the ability tounderstand
and willingness to sign an informed consent document.
Patients receiving bisphosphonate therapy had to discontinue
their treatment for at least 3 months before study entry, and
patients under luteinising hormone–releasing hormone ago-
nists had to continue their treatment. Patients with pathologic
long-bone fractures or metastatic involvement of >75% of the
ribs, vertebrae and pelvic bones and patients with known
malignancies other than prostate cancer (not including basal
cell carcinoma of the skin) were excluded. Other exclusion
criteria were chemotherapy (including Estracyt®) within the
past 5 years; prior treatment with systemic radiotherapeutic
bone agents; receipt of any other investigational drug within
4 weeks ofstudyentry;previoushemi-body externalradiation
therapy (for >25% of the bone marrow within 90 days);
concomitant treatment with aminoglycosides; clinically sig-
nificant bleeding disorders; hypersensitivity to phosphonate
compounds, mannitol or zoledronic acid; concurrent illnesses
or treatments that might preclude study completion; active
central nervous system or epidural brain metastasis; absolute
neutrophil count <2×10
9/l; platelet count <150×10
9/l;
hemoglobin <6.2 mmol/l; serum creatinine >177 μmol/l; or
total prostate-specific antigen (PSA) <5 ng/ml. The study
was approved by the local ethics committee, and written
informed consent was obtained from all patients.
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Included patients were treated with 18.5 MBq/kg (0.5 mCi/kg)
153Sm-ethylenediaminetetramethylphosphonic acid (EDTMP;
Quadramet®; CIS bio International, Saclay, France) in week 1
(mean±1 SD, 1,606±252 MBq) and week 3 (mean±1 SD,
1,672±293 MBq) and with 37 MBq/kg (1.0 mCi/kg)
153Sm-
EDTMP in week 15 (mean±1 SD, 3,319±609 MBq). The
three intravenous injections contained the same absolute
amount of EDTMP.
To avoid an effect of progressive disease with significant
changes in skeletal metastatic load, a short interval of
2 weeks was chosen between the first two treatments. Half
the usual dose of
153Sm-EDTMP was administered to avoid
unacceptable toxicity. Although this regimen is unusual, it
seems acceptable from a therapeutic standpoint. A dose
response relation for
153Sm-EDTMP was not clearly found
in all studies [16]. Furthermore, repeated treatments at short
intervals have shown favourable responses [17]. The
interval between the second and third treatment with
153Sm-EDTMP (12 weeks) was chosen to allow (a) bone
marrow recovery from the first two treatments and (b) four
consecutive administrations of zoledronic acid before the
third
153Sm-EDTMP treatment. Another 12-week interval
between the third treatment and the final visit in week 27
was chosen to allow bone marrow recovery.
Treatment with 4 mg zoledronic acid (Zometa
®;N o v a r t i s ,
Stein, Switzerland) every 4 weeks started in week 3 and
continued through week 23 (six treatments total). In weeks 3
and 15, zoledronic acid was administered 2 days (48 h)
before
153Sm-EDTMP treatment. Zoledronic acid treatments
were injected as single 15-min intravenous infusions in a
daycare setting. After infusion, vital signs were recorded
every 30 min for the first 2 h, after which, patients were
discharged. In weeks 1, 3 and 15, patients were hospitalised
for 48 h after
153Sm-EDTMP administration. Urine was
collected during the 48 h after injection of
153Sm-EDTMP in
five portions (0–4, 4–8, 8–12, 12–24 and 24–48 h). Whole-
body images were captured with a dual-head gamma camera
at 6, 24 and 48 h post-injection (anterior and posterior).
Patients with lower urinary tract obstruction or incontinence
had to consent to catheterisation of the bladder for up to 48 h.
Analysis
After intravenous injection of
153Sm-EDTMP, most of the
activity is rapidly cleared from the blood and excreted in
urine. No appreciable extraskeletal uptake was observed on
the scintigraphic images because the remaining activity in
the body was almost completely localised to the skeletal
mass. Previous animal studies confirm the minimal uptake of
153Sm-EDTMP by extraskeletal tissues [4, 18]. Therefore,
the uptake of
153Sm-EDTMP by the whole skeleton was
studied indirectly by measuring the urinary excretion of
activity [19, 20].
After the initial injection of
153Sm-EDTMP, urine was
collected over the next 48 h. The amount of activity in these
samples was determined by measurement of 15-ml non-
diluted samples with a dose calibrator. For comparison with
the administered activity, the exact injected dose was
determined by measurement of the syringe before and after
administration. This procedure enabled determination of the
amount of activity excreted and, as a corollary, the relative
amount of activity retained within the body. The primary
endpoint of the study was the effect of zoledronic acid on the
urinary excretion of
153Sm-EDTMP, which was measured in
weeks 1 and 3, i.e. before and after the first zoledronic acid
infusion. The effect of repeated zoledronic acid treatment on
the urinary excretion of
153Sm-EDTMP in weeks 1 and 15
was a secondary endpoint.
Secondary endpoints also included the effects of the
combined use of zoledronic acid and
153Sm-EDTMP on the
uptake of
153Sm-EDTMP in bone metastases, liver and
kidneys. The scintigraphic images were evaluated by an
independent certified nuclear physician with expertise in
skeletal scintigraphy, blinded for patient data and the week
the images were acquired. Images of each week (6, 24 and
48 h after injection) were shown together for each patient, as
the reader could anyhow identify the different points in time
by the decrease in activity. The reader started with the ‘6-h’
image and drew regions of interest (ROIs; at least 25 pixels)
for three metastatic bone lesions, normal bone (femur),
background (soft tissue of the thigh), the liver (ROIs without
overlap of ribs. Anterior image: paravertebral space at height
Th11–Th12; posterior image: interribonspace 9–10 or 10–11)
and kidneys (arithmetic mean of both kidneys was used).
ROIs were copied to the other images of the same patient.
From all ROIs, 30% isocontour ROIs were automatically
drawn. Geometric means of anterior and posterior images
were calculated for these ROIs and corrected for back-
ground. Evaluation of biodistribution was based on a
quantitative analysis of the pixel-normalised lesion-to-normal
bone ratios and pixel-normalised organ-to-normal bone
ratios. Blood sampling was not performed.
Other secondary endpoints were the following: safety
and tolerability of the combined use of
153Sm-EDTMP and
zoledronic acid (vital signs, laboratory values and adverse
events according to the NCI Common Terminology Criteria
for Adverse Events, version 3.0), the effect on markers of
bone metabolism as measured in blood and urine samples
[serum bone-specific alkaline phosphatase (BAP), serum
procollagen type 1 N propeptide (PINP) and the urinary N-
terminal type 1 collagen peptide (NTX)] and the effect on
PSA levels.
The present study was not designed to investigate the
efficacy of the combined treatment.
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Descriptive statistics [n, mean, standard deviation (SD),
minimum, quartile 1 (Q1), median, quartile 3 (Q3), and
maximum] were calculated for quantitative variables; fre-
quency counts by category were determined for qualitative
variables. A bioequivalence test was performed using the
classical 90% confidence interval method for the ratio of the
cumulated activities excreted in urine within 48 h after
administration in weeks 3 and 1 [(excreted urine week 3)/
(excreted urine week 1)×100%]. For a broad range of drugs,
the Food and Drug Administration (FDA) has chosen a limit
of 80–125% for the confidence interval of a bioequivalence
test. Generally, the limit of 80–125% is based on a clinical
judgment that a test product with measures outside this range
should be denied market access. If the confidence interval
lay completely within the equivalence interval of 80–125%,
equivalence was concluded.
Theprimarytargetvariablewasanalysedwithatwo-sample
t test. It was assumed that this parameter was log-normally
distributed; therefore, the logarithms (base e) were analysed.
Results
A total of 20 patients were enrolled in this study. Two
patients were not treated because of low platelet counts.
Major protocol deviations leading to exclusion from
analysis of the primary objective were found in five
patients. One patient had not stopped anti-androgen
medication; one patient received a dosage in week 3 higher
than the required dose due to miscalculation of his weight,
and this patient also started anti-androgen treatment; one
patient went off-study before treatment in week 3 due to
progressive disease (lymphangitis carcinomatosa); and two
patients had no or incomplete urine collection. Thus, 18
patients were included in the full-analysis set (FAS) and 13
in the per-protocol set (PPS). All patients in the FAS were
white with a mean age of 67.3 years (range 61–74).
Among the 18 patients who entered the treatment period,
seven withdrew before the end of the treatment period
(before week 23), and 11 completed both the treatment
period and the study course (27 weeks). Two patients were
withdrawn because of adverse events (increase in creatinine
level, disseminated intravascular coagulation), four patients
were recommended to start with radiotherapy or chemother-
apy because of progressive disease, and one patient was
withdrawn due to decreasing PSA level after the start of anti-
androgen treatment.
Of the 18 included patients, 13 were evaluable for the
primary endpoint (PPS). Urinary excretion data expressed
as percentage of administered activity are shown in Table 1.
The mean ratio of urinary excretion of
153Sm in week 3 to
that at baseline (week 1) expressed as a percentage was
98.4±11.6% (median 96.2%, range 81.1–118.9%; Table 2).
Table 1 Urinary excretion of
153Sm-EDTMP (percentage of admin-
istered activity)
Patient Week 1 Week 3 Week 15
1 36.3 9.2
a 39.3
2 48.5 57 55.9
3 Screening failure
b
4 37.6 44.7 42.8
5 43.7 46 44.3
6 55.6 48.8 50.2
7 43.8 46.7 50.1
8 –
a 37.8 Off study
9 43.5 49.2 48.5
10 47.5 43.1 48.6
11 Screening failure
b
12 46.6 49.2 47
13 32 30 Off study
14 38.1 37 31.7
15 30.8 27.1 Off study
16 33.7 38.1 Off study
17 31.8 25.8 Off study
18 39.6 38.1 37.1
19 39.8 36.3 41.1
20 51.2 Off study Off study
aCollection of urine was not complete/not performed
bExclusion due to low trombocyte count
Table 2 Descriptive statistics of ratios (%) of urinary excretion of
153Sm-EDTMP
N Mean (%) SD Min Q1 Median (%) Q3 Max
Week 3/Week 1
PPS 13 98.44 11.58 81.13 90.74 96.21 105.58 118.88
FAS 16 95.70 22.00 25.34 89.36 96.66 109.84 118.88
Week 15/Week 1
PPS 10 101.85 10.71 83.20 93.69 101.84 113.83 115.26
FAS 12 103.18 10.20 83.20 97.27 102.79 112.66 115.26
Week 15/Week 3
PPS 10 100.48 8.59 85.68 95.75 97.72 107.28 113.22
FAS 12 127.55 94.68 85.68 96.03 98.32 110.02 427.17
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assessment of bioequivalence were 97.83% (92.39–
103.60%) for weeks 1 to 3, which was completely within
the presumed equivalence range used by the FDA (80–
125%). Hence, bioequivalence could be concluded.
As shown in Fig. 1, there was no change in the fraction
of
153Sm-EDTMP excreted in urine after one administration
of zoledronic acid (week 3) or after repeated administra-
tions of zoledronic acid (week 15) compared with the
urinary excretion at baseline (week 1). Descriptive statistics
were similar in the PPS and the FAS except for the mean
ratio of
153Sm-EDTMP excretion between weeks 15 and 3,
which was higher for FAS (127.55%) due to the low value
of urinary excretion in one patient at week 3. This patient
was excluded from the PPS because the collection of his
urine at week 3 was not complete (Tables 1 and 2).
The uptake of
153Sm-EDTMP in bone metastases or
organs vs uptake in normal bone was determined by
calculation of the lesion- or organ-to-normal bone ratios at
each time point (skeletal scintigrams were obtained 6, 24
and 48 h post-injection). Figure 2 shows the uptake of
153Sm-EDTMP in normal bone 6, 24 and 48 h after each
administration of
153Sm-EDTMP. The uptake of activity in
normal skeleton was dosage- and time-dependent because it
decreased with increasing time after injection (from 6 to
48 h post-injection) and increased proportionally with
increased injected dose (18.5 MBq/kg at weeks 1 and 3
vs 37 MBq/kg at week 15).
153Sm-EDTMP was bound to
the bone in a stable manner because the decrease in uptake
between 6 and 48 h was due solely to the physical decay of
153Sm. Importantly, the FAS results showed no effect of one
dose (week 3) or repeated doses (week 15) of zoledronic
acid on the uptake of
153Sm-EDTMP by normal bone.
Similar results were obtained for the PPS.
The
153Sm-EDTMP uptake ratios of metastases/normal
bone, kidneys/normal bone and liver/normal bone were
calculated at baseline (week 1), week 3 and week 15.
Figure 3 shows the differences between these time points
given as ratios, e.g. ratio of metastases/normal bone at
week 3 to metastases/normal bone at baseline×100%
(given numbers are thus ratios of ratios). The uptake of
153Sm-EDTMP in bone metastases was relatively insensi-
tive to variation in the injected dose of
153Sm-EDTMP and
to repeated administrations of zoledronic acid and
153Sm-
EDTMP. In addition, the uptake of
153Sm-EDTMP in
kidneys and liver was not affected by the activity of the
Fig. 1 Urinary excretion of
153Sm-EDTMP in week 3 (combined
therapy with zoledronic acid) divided by urinary excretion of
153Sm-
EDTMP in week 1 (without zoledronic acid) times 100%. Also, for
week 15 (after repeated zoledronic acid administrations) vs week 1
and week 15 vs week 3. All data for the per-protocol set (PPS).
Zoledronic acid does not change the excretion nor the uptake of
153Sm-EDTMP because no changes between different weeks were
observed (all ratios are close to 100%)
Fig. 2 Mean (±1 SD) uptake (counts per pixel) of
153Sm-EDTMP in
normal bone in post-treatment skeletal scintigrams obtained 6, 24 and
48 h after administration for the full-analysis set (FAS) .W e e k s1 ,3 ,a n d
15 are compared. q=18.5 MBq/kg
153Sm-EDTMP, Q=37 MBq/kg
153Sm-EDTMP; Z Zoledronic acid
Fig. 3 Per patient (FAS), a total of nine scintigrams were performed
at three different weeks (weeks 1, 3 and 15) and three different time
points post injection (6, 24 and 48 h p.i.). Lesion-to-normal bone
ratios were calculated on every scintigram. Comparison between
different weeks were made for every time point post-injection as
follows: [lesion-to-normal bone ratio] week 3, 6 h p.i. divided by
[lesion-to-normal bone ratio] week 1, 6 h p.i., times 100%. Zoledronic
acid does not change the uptake of
153Sm-EDTMP in lesions
compared to normal bone (all ratios are close to 100%)
760 Eur J Nucl Med Mol Imaging (2008) 35:756–765injected dose of
153Sm-EDTMP or by repeated adminis-
trations of zoledronic acid and
153Sm-EDTMP. Similar
results were obtained for the FAS and the PPS. No
significant changes were found. None of the images
showed liver uptake or any other extraskeletal uptake
besides kidneys and bladder. Activity in the kidneys and
bladder was only visualised on the early images.
Blood sampling was not performed. Blood plasma
activity clearance was therefore not measured. Because
uptake in normal bone, metastatic bone and organs, as well
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Fig. 4 Mean hematological
parameters (FAS) during the
whole study period: hemoglobin
(a), platelet count (b)a n dw h i t e
blood cell count (c)
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to assume that the retention of activity in the blood pool
compartment did not change either. Any change in the
retention of activity in this compartment would lead to a
secondary change in either urinary excretion of activity or
uptake in the skeleton. This hypothesis is supported by
stable and low background activity as measured in the
thigh. Besides minimal visualisation of activity in soft
tissue, the measured soft tissue activity was approximately
30–40 times less than normal bone activity [0.6±0.1 counts
per pixel compared to 22.1±5.7 counts per pixel 6 h p.i. in
week 1; 0.7±0.1 counts per pixel compared to 22.3±4.3
counts per pixel 6 h p.i. in week 3 (PPS)].
After onset of the study treatment, hematological param-
eters were measured on a weekly basis (Fig. 4) and serum
chemistry (including creatinine level) on a monthly basis.
All patients experienced the expected temporary decline in
platelet count in week 5 (mean±1 SD, 42.2±18.8% decline,
4 weeks after the first
153Sm-EDTMP administration) and
in week 19 (64.3±9.9% decline, 4 weeks after the third
153Sm-EDTMP administration), with subsequent recovery.
In addition, as expected, there was a temporary decline in
white blood cell count in week 7 (36.5±23.8% decline,
6 weeks after the first
153Sm-EDTMP administration) and
in week 20 (40.5±15.2% decline, 5 weeks after the third
153Sm-EDTMP administration), with recovery thereafter.
Hemoglobin levels steadily declined throughout the study
course with a mean decrease of 12.5±8.0% at the end of the
study compared with baseline. This is consistent with the
disease progression (PSA increase) observed for most
patients during the study course.
Grades 2, 3, and 4 hematological toxicity occurred in 12, 1
and 2 patients, respectively. Creatinine levels were stable
throughout the study period for all, except one patient who
experienced a sudden increase in creatinine level (grade 2) in
week10(aftertwodoses of18.5MBq/kg
153Sm-EDTMP and
two infusions of 4 mg zoledronic acid) due to bilateral ureter
obstruction caused by pathologically enlarged lymph nodes.
This patient went off-study, and creatinine levels returned to
normal after relief of the obstruction.
Other adverse events included pain and fatigue due to
disease progression and ‘influenza-like symptoms,’ nausea,
vomiting and hypocalcemia related to zoledronic acid
administration. One patient experienced a pathological hip
fracture, and another patient had monoparesis as a result of
epidural metastatic disease. A third patient had disseminated
intravascular coagulation, causing him to develop grade 3
hematoma and grade 4 thrombopenia. These patients went
off-study. No further unexpected toxicity occurred (Table 3).
Secondary endpoints for efficacy were bone metabolism
markers and PSA response. Figure 5 shows the change
from baseline of bone metabolism markers (FAS). Urinary
NTX corrected to creatinine excretion, which reflects bone
resorption, was reduced markedly, falling rapidly (median
decrease ~70%) within 1 month after the first administra-
tion of zoledronic acid (week 3) and remaining suppressed
during the entire study course. Serum BAP, reflecting bone
formation by osteoblasts, decreased, with a mean reduction
of ~25% at week 15. An additional 25% decrease in BAP
was noticed after the administration of a full dose of
153Sm-
EDTMP at week 15, leading to a 50% total decrease from
Table 3 Number of patients experiencing adverse events
Grade
1
Grade
2
Grade
3
Grade
4
Disseminated intravascular
coagulation
––1 –
Abdominal pain 4 –––
Constipation 4 –––
Diarrhea 2 –––
Nausea 6 1 1 –
Vomiting 1 – 2 –
Asthenia 2 1 ––
Crepitations – 1 ––
Fatigue 1 1 1 –
Influenza-like illness 13 –––
Malaise 1 1 ––
Pain 4441
Pyrexia 3 –––
Hip fracture ––1 –
Anaemia 4 7 – 1
Leucopenia 4 8 0 –
Neutropenia 1 7 1 –
Thrombopenia 12 2 – 2
Hypocalcaemia 11 1 2 –
Creatinine increase 1 1 ––
Urea increase 3 1
Weight decreased 7 –––
Dizziness 2 1 ––
Headache 5 1 ––
Monoparesis –––1
Paraesthesia 2 –––
Euphoric mood – 1 ––
Obstructive uropathy – 1 ––
Urinary retention 2 –––
Cough 2 1 ––
Dysnpoea – 3 ––
Epistaxis 2 –––
Haemoptysis 2 –––
Hypoxia ––1 –
Hyperhidrosis 3 –––
Night sweats 2 –––
Haematoma ––1 –
Hypertension 4 2 ––
Lymphangitis – 1 ––
This table includes adverse events which are related or unrelated to
study drugs, with either an intensity >grade 1 (according to NCI
Common Terminology Criteria for Averse Events) or frequency >1
patient
762 Eur J Nucl Med Mol Imaging (2008) 35:756–765baseline. The increase in BAP at week 15 may reflect some
disease progression before the
153Sm-EDTMP treatment at
week 15. Serum PINP decreased progressively over
15 weeks to a mean reduction of 50% after four to five
repeated administrations of zoledronic acid.
Baseline levels of total PSA measured before adminis-
tration of the study drugs ranged from 15 to 2,400 ng/ml.
Of the 18 treated patients, 14 had baseline levels <400 ng/ml
and four had baseline levels >1,000 ng/ml. After the start
of treatment, PSA levels of the 15 evaluable patients (two
patients did not stop or started anti-androgen treatment,
one patient went off-study before week 3) were either
increasing (nine patients), stabilised (three patients) or
decreasing (three patients). Eight weeks after the final
administration of
153Sm-EDTMP in week 23, PSA levels in
most patients had increased by >50%, reflecting prostate
cancer progression. Two patients had remarkably decreased
PSA levels [from 24 to 6.9 μg/l (−71%) and from 30.7 to
17.6 μg/l (−43%)] at week 23.
Discussion
Various therapies for the treatment of painful skeletal
metastases are currently available. These can be in the
form of local or systemic therapy and include analgesics,
chemotherapy, hormonal therapy, surgery, bisphosphonates,
external beam radiation and systemically administered
radiopharmaceuticals. A multidisciplinary approach to the
treatment of cancer pain has been advocated [20]. Besides
optimising radiopharmaceutical dosing schemes and treat-
ment regimens [21, 22], synergy between different pharma-
ceuticals could ultimately enhance efficacy to move beyond
mere palliation [6].
The combined use of bisphosphonates and bone-seeking
radiopharmaceuticals could have clinical benefit [9]. The
prevention of skeletal-related events could have an additive
effect on the palliative treatment of bone-seeking radio-
pharmaceuticals. Nevertheless, the European label of
153Sm-EDTMP includes the contraindication that “it should
not be used concurrently with other bisphosponates if an
interference is shown on the
99mTc-labelled bisphosphonate
bone scan.” This contraindication is based on the hypoth-
esis that as both drugs interact at the hydroxyapatite crystal
surface of the skeleton, competition might exist for uptake
by bone. However, the present study shows that the
combined use of zoledronic acid has no effect on the
uptake of
153Sm-EDTMP in skeletal metastases of hor-
mone-refractory prostate carcinoma. These results are
consistent with the American label of
153Sm-EDTMP,
which does not include the contraindication of the
combined use of
153Sm-EDTMP with other bisphospho-
nates. The present results show that combining
153Sm-
EDTMP and zoledronic acid is both feasible and safe. No
competition for uptake by bone was observed, and only the
known adverse drug reactions associated with
153Sm-
EDTMP and zoledronic acid were encountered. Regarding
the conflicting data on the effect of bisphosphonates on
radiolabelled phosphonates, it should be noted that reduced
uptake observed on
99mTc-labelled bone scans after
initiating therapy with bisphosphonates does not necessarily
indicate an interaction between these agents. The reduced
uptake of radiolabelled phosphonates could also reflect a
true decrease in metabolic bone activity due to the
therapeutic effect of the bisphosphonates, especially when
repeated bone scintigraphy takes place after a long interval
of bisphosphonate treatment [23]. This was not the case in
the present study.
Secondly, in studies that reported an adverse interaction
between bisphosphonates and radiolabelled phosphates,
bisphosphonates were administered because of malignan-
cy-induced hypercalcemia [10, 12]. High serum calcium
levels may lead to complex formation between calcium ions
and radiolabelled phosphates, resulting in impaired imaging
[24]. Furthermore, in patients with malignant hypercalce-
mia in association with renal failure, progressive soft tissue
uptake of radiolabelled phosphates may occur due to
metastatic microcalcification. This soft tissue uptake may
occur at in vivo calcium phosphate ion product concen-
trations of >5m m o l
2/l
2 [25, 26]. In patients with normal
calcium levels, interactions between bisphosphonates and
radiolabelled phosphates could not be confirmed. In
patients with prostate cancer treated with alendronate (oral
40 mg daily) and in patients with breast cancer treated with
clodronate (i.v. 300 mg daily), no effects of these
bisphosphonates on repeated bone scintigraphy were
observed [13, 15]. All patients in our study had either
normal or below-normal serum calcium levels throughout
the study course.
Fig. 5 Median change (%) from baseline of bone markers during the
study period of 27 weeks (FAS). BAP Serum bone-specific alkaline
phosphatase, PINP serum procollagen type 1 N propeptide, corr NTX
urinary creatinine-corrected N-terminal type 1 collagen peptide
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ical markers reflecting the overall rate of bone formation and
bone resorption has improved the noninvasive assessment of
bone turnover abnormalities in patients with prostate cancer.
Several studies have shown a rapid decrease in bone
resorption markers in patients with prostate cancer and bone
metastases after treatment with bisphosphonates. It has been
reportedthatthe magnitude ofthe decreasecorrelatedwiththe
efficacy of the treatment [27, 28]. Our results are consistent
with data reported by Saad et al. [7] for metastatic prostate
cancer patients treated with zoledronic acid (4 mg every
3 weeks). In our study, urinary NTX corrected to creatinine
excretion showed a 70% decrease and remained suppressed
during the entire study course. Serum BAP decreased, with a
mean reduction of ~25% at week 15. Similarly, Saad et al.
reported a 25% decrease in serum BAP, which was stable for
~1 year, in hormone-refractory prostate cancer patients
treated with zoledronic acid. However, in our study, an
additional 25% decrease in BAP was observed after
administration of a full dose of
153Sm-EDTMP at week 15,
leading to a 50% total decrease from baseline. The additional
decrease may be attributed to a BAP-reducing effect of
153Sm-EDTMP. In support of this idea, the bone markers had
already started to decrease after
153Sm-EDTMP treatment
alone. Bone marker responses may suggest an additive effect
of the two treatments. Besides that, it is interesting to note
that while bone markers declined, most patients showed a
PSA increase. Presumably, the decrease in bone metabolism
was not enough to lead to an objective anti-tumour effect in
this study population. However, the present study was not
designed to investigate the efficacy of combined treatment
because the number of treated patients is small. Although
overall results on PSA decline do not seem to parallel the
data on bone marker decline, two patients did respond very
well. In addition to a remarkable and durable PSA decline
(−71 and −43% at week 23), all bone markers decreased
(−65 and −90% at week 23), and clinical responses were
complete.
To enhance the efficacy of bone-seeking radiopharma-
ceuticals, the search for effective combination therapies is
crucial. Individual patients in our study responded very
well to the combined treatment of bisphosphonates and
bone-seeking radiopharmaceuticals. In these patients, sig-
nificant bone marker decline paralleled a significant clinical
and PSA response. Because the present study was not
designed for evaluating treatment efficacy, the value of this
particular combination therapy merits further investigation.
Furthermore, it is of growing importance for the optimisa-
tion of palliative treatment and enhancement of efficacy to
characterise the bone marker responses of those patients
that respond well to the proposed treatment regimen. This
characterisation may prove important for individualised
therapy monitoring.
Conclusion
Combined treatment with the bisphosphonate zoledronic
acid has no effect on the skeletal uptake of
153Sm-EDTMP
in patients with hormone-refractory prostate carcinoma and
normal calcemia. Combined treatment is feasible and safe.
The potential additive effect on efficacy of the two
treatments should be studied in future trials.
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